Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
FDA expands approval for drug to treat early-stage breast cancer
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...
The American Journal of Managed Care5d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
NBC New York5d
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
Today4d
FDA expands approval of breast cancer drug Kisqali: What to know
The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens of ...
Science Daily4d
Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder
A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
Cure Today5d
FDA Approves Kisqali Regimen for HR+/HER2- Early Breast Cancer
Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence. The Food and Drug Administration (FDA) has approved ...